Download PDF
Thromb Haemost 1997; 78(01): 730-735
DOI: 10.1055/s-0038-1657620
Newer antithrombotic agents
Schattauer GmbH Stuttgart

GPIIb/IIIa Antagonists: Pathophysiologic and Therapeutic Insights from Studies of c7E3 Fab

Barry S Coller
Department of Medicine, Mount Sinai School of Medicine, New York, N.Y., USA
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol 1994; 31: 301-311
    PubMedGoogle Scholar
  • 2 Weiss HJ, Turitto VT, Baumgartner HR. The role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium: studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest 1986; 78: 1072-1082
    CrossrefPubMedGoogle Scholar
  • 3 Coller BS. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Art Dis 1992; 03: 1016-1029
    CrossrefPubMedGoogle Scholar
  • 4 The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
    CrossrefPubMed
  • 5 Topol EJ, Califf RM, Weismann HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M. et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886
    CrossrefPubMedGoogle Scholar
  • 6 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559
    CrossrefPubMedGoogle Scholar
  • 7 Abciximab package insert. 1995
    PubMed
  • 8 Jordan RE, Wagner CL, Mascelli M, et al. Horton MDMA. editors. Adhesion Receptors as Therapeutic Targets. Boca Raton: CRC Press, Inc.; 1996. 15. Preclinical development of c7E3 Fab; a mouse/human chimeric monclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. p. 281-305
    Google Scholar
  • 9 Simoons ML, de Boer MJ, van den Brand MJ, van Mittenburg AJ, Hoorntje JC, Hegndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF. et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603
    CrossrefPubMedGoogle Scholar
  • 10 Christopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 1993; 04: 729-737
    CrossrefPubMedGoogle Scholar
  • 11 Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab Patients with Glanzmann thrombasthenia in Israel. Blood 1991; 77: 75-83
    PubMedGoogle Scholar
  • 12 Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993; 05: 864-868
    CrossrefPubMedGoogle Scholar
  • 13 Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-914
    CrossrefPubMedGoogle Scholar
  • 14 Wencel-Drake J. Plasma membrane GPIIb/IIIa. Evidence for a cycling receptor pool. Am J Pathol 1990; 36: 61-70
    PubMedGoogle Scholar
  • 15 Pike NB, Lumley P. Uptake of a fibrinogen receptor antagonist by human platelets appears dependent upon GPIIb/IIIa. [Abstract] Thromb and Haemostas 1995; 73: 1195
    PubMedGoogle Scholar
  • 16 Morgenstern E, Ruf A, Patscheke H. Transport of anti-glycoprotein IIb/IIIa-antibodies into the alpha-granules of unstimulated human blood platelets. Thromb and Haemostas 1992; 67: 121-125
    PubMedGoogle Scholar
  • 17 Peerschke El. Adhesive protein expression on thrombin-stimulated platelets: time-dependent modulation of anti-fibrinogen, -fibronectin, and -von Willebrand factor antibody binding. Blood 1992; 79: 948-953
    PubMedGoogle Scholar
  • 18 Gralnick HR, Williams SB, McKeown L, Shafer B, Connaghan GD, Hansmann K, Vail M, Magruder L. Endogenous platelet fibrinogen: its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen. Br J Haematol 1992; 80: 347-357
    CrossrefPubMedGoogle Scholar
  • 19 Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995; 26: 1665-1671
    CrossrefPubMedGoogle Scholar
  • 20 Wagner CL, Cunningham MR, Wyand MS. et al. Reversal of the anti-platelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys. [Abstract] Thromb Haemostas 1995; 73: 1313
    PubMedGoogle Scholar
  • 21 Lincoff AM, Tcheng JE, Califf RM. et al. Standard versus low dose weight-adjusted heparin in patients treated with the platelet GPIIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. [In Press] Am J Cardiol. 1997
    Google Scholar
  • 22 Ward SR, Lincoff AM, Miller DP. et al. Clinical outcome is improved at 30 days regardless of pre-treatment clinical and angiographic risk in patients receiving abciximab for angioplasty: results from the EPILOG study. [Abstract] Circulation 1996; 94 (Suppl.) 001-198
    CrossrefPubMedGoogle Scholar
  • 23 Aguirre FA, Talley DJ, Ferguson III JJ, Tcheng J, Kleiman NS, Montague EA, Booth JE, Lincoff AM. Efficacy of abciximab, despite patient weight, using lower heparin dosing during percutaneous coronary intervention. Circulation 1996; 94 (Suppl.) 001-198
    CrossrefPubMedGoogle Scholar
  • 24 Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy. (Submitted)
    PubMedGoogle Scholar
  • 25 Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996; 78: 1161-1166
    CrossrefPubMedGoogle Scholar
  • 26 Christopoulos CG, Machin SJ. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody. Br J Haematol 1994; 87: 650-652
    CrossrefPubMedGoogle Scholar
  • 27 Bednar B, Bednar RA, Cook JJ, Booag DM, Chang CT, Gaul SL, McQueney PA, Egbertson MS, Hartman GD, Holahan MA. et al. Drug-dependent antibodies against GPIIb/IIIa induce thrombocytopenia. Circulation 1996; 94: 01-99
    CrossrefPubMedGoogle Scholar
  • 28 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338
    CrossrefPubMedGoogle Scholar
  • 29 Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced, thrombin generation by the mouse/human chimeric 7E3 anibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest 1996; 98: 863-874
    CrossrefPubMedGoogle Scholar
  • 30 Coller BS. Augmentation of thrombolysis with antiplatelet drugs. Overview. Coron Art Dis 1996; 6: 911-914
    PubMedGoogle Scholar
  • 31 Cox AD, Devine DV. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. Blood 1994; 83: 1006-1016
    PubMedGoogle Scholar
  • 32 Carr Jr. ME, Carr SL, Hantgan RR. Braaten J. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus. Thromb Haemost 1995; 73: 499-505
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Schwartz SM, Liaw L. Growth control and morphogenesis in the development and pathology of arteries. J Cardiovasc Pharmacol 1993; 21 (Suppl. 01) S31-S49
    CrossrefPubMedGoogle Scholar
  • 34 Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994; 90: 1908-1918
    CrossrefPubMedGoogle Scholar
  • 35 Schwartz SM. Serum-derived growth factor is thrombin?. J Clin Invest 1993; 91: 04
    CrossrefPubMedGoogle Scholar
  • 36 Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-562
    CrossrefPubMedGoogle Scholar
  • 37 Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet GPIIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. [In Press] Circulation. 1997
    Google Scholar
  • 38 Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking avb3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19: 125-134
    CrossrefPubMedGoogle Scholar
  • 39 Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-2206
    CrossrefPubMedGoogle Scholar
  • 40 van der ZeeR, Passeri J, Barry JJ. et al. A neutralizing antibody to the alpha v beta 3 integrin reduces neointimal thickening in a balloon-injured rabbit iliac artery. [Abstract] Circulation 1996; 98 (Suppl.) 001-257
    PubMedGoogle Scholar
  • 41 Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. Am J Cardiol 1994; 74: 1166-1170
    CrossrefPubMedGoogle Scholar
  • 42 Coller BS, Lang D, Scudder LE. A rapid and simple platelet function assay to assess GPIIb/IIIa receptor blockade. [In Press] Circulation. 1997
    Google Scholar